GLP-1 Benefits Beyond Weight Loss: Real Risks Too

GLP-1 Drugs Are About More Than the Scale

If you started researching Ozempic or Wegovy because you wanted to lose weight, you're not alone. But the science on these medications has expanded well beyond the number on your scale.

GLP-1 receptor agonists, drugs that mimic a natural hormone called glucagon-like peptide-1, are now showing measurable benefits for your heart, kidneys, liver, and even your breathing at night. At the same time, the risk profile of these medications deserves an honest look before you decide to start.

This is not about hype in either direction. It's about giving you the full picture so you can have a smarter conversation with your doctor.

What GLP-1 Medications Are Actually Approved For

The FDA has approved specific GLP-1 drugs for specific conditions. It's worth knowing exactly where the approvals stand right now.

Semaglutide (Ozempic and Wegovy)

Ozempic (semaglutide 0.5 mg to 2 mg) is approved for type 2 diabetes management. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

In 2024, the FDA also approved Wegovy to reduce the risk of serious cardiovascular events like heart attack and stroke in adults with cardiovascular disease and obesity or overweight. This was a landmark decision. It was the first time a weight-loss drug received approval specifically for heart protection.

Tirzepatide (Mounjaro and Zepbound)

Mounjaro (tirzepatide) is approved for type 2 diabetes. Zepbound (the same drug at the same doses) is approved for chronic weight management. In late 2024, Zepbound also received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first medication ever approved for that condition.

The Cardiovascular Evidence Is Compelling

The SELECT trial, published in the New England Journal of Medicine in 2023, followed more than 17,000 adults with obesity or overweight and established cardiovascular disease. None had diabetes. Participants taking semaglutide 2.4 mg experienced a 20% reduction in major adverse cardiovascular events compared to placebo over roughly three years.

That kind of reduction is clinically significant. It suggests semaglutide may be protecting the heart through mechanisms beyond weight loss alone, possibly by reducing inflammation, improving blood vessel function, or stabilizing arterial plaques.

For patients who have already had a heart attack or stroke, or who have been diagnosed with heart disease, this evidence is particularly relevant. It moves semaglutide from a weight-loss tool into a broader cardiovascular risk-reduction therapy.

Kidney and Liver Benefits Are Emerging

Kidney Disease

A 2024 trial called FLOW, published in the New England Journal of Medicine, showed that semaglutide reduced the progression of chronic kidney disease in people with type 2 diabetes. It lowered the risk of serious kidney events by 24% compared to placebo. The trial was actually stopped early because the benefit was so clear.

This matters because kidney disease affects roughly 1 in 7 American adults, and it often progresses silently. For patients managing both diabetes and chronic kidney disease, semaglutide may now represent a two-in-one benefit.

Fatty Liver Disease

Metabolic dysfunction-associated steatohepatitis, or MASH (formerly called NASH), is liver inflammation caused by fat buildup. Semaglutide has shown promise in clinical trials for improving liver histology, meaning it can reduce the fat and inflammation seen on liver biopsy. Resmetirom (brand name Rezdiffra) is currently the only FDA-approved treatment specifically for MASH, but semaglutide trials are ongoing and results look encouraging.

Sleep Apnea: A Surprising New Benefit

The approval of tirzepatide for obstructive sleep apnea was unexpected by many patients. Obstructive sleep apnea occurs when excess weight causes soft tissue to block the airway during sleep. It affects an estimated 30 million Americans, many of whom go undiagnosed.

The SURMOUNT-OSA trials showed that tirzepatide reduced the number of breathing disruptions per hour by roughly 55% in patients not using a CPAP machine, and by about 63% in patients who were using one. These are not small improvements. Some participants saw their sleep apnea reclassified from severe to mild, or resolved entirely.

For patients who have struggled with CPAP compliance or who did not know their weight was driving their sleep problems, this represents a meaningful new option.

Mental Health Effects: Early and Ongoing Research

Several observational studies and some trial data have suggested that GLP-1 medications may reduce symptoms of depression and anxiety in some patients. The mechanisms are not fully understood, but researchers believe it may relate to the drug's effects on brain reward pathways, inflammation, and the gut-brain axis.

There is also emerging interest in GLP-1s as a potential tool in addiction medicine, with early studies looking at reduced cravings for alcohol and nicotine. These are not approved uses and should not be reasons to seek out these medications independently. But they reflect just how broadly these drugs may ultimately prove useful.

It's worth noting that the FDA added a warning to GLP-1 drugs after some reports of suicidal ideation, though later analysis found no clear causal link. Your mental health history is still something to discuss with your prescriber before starting.

The Real Risks You Should Not Overlook

A thorough look at GLP-1 benefits is incomplete without an equally honest look at risks. These are real, documented, and worth understanding before you start.

Gastrointestinal Side Effects

Nausea, vomiting, diarrhea, and constipation are the most common side effects. In clinical trials, nausea affected up to 44% of semaglutide users at higher doses. These symptoms tend to peak during dose escalation and improve over time for most patients, but they can be severe enough to cause some people to discontinue treatment.

Eating smaller meals, avoiding high-fat foods, and taking your injection on a consistent schedule can help. Your prescriber can also adjust your dose escalation timeline if side effects are too disruptive.

Muscle Loss

Weight loss from any method includes some muscle loss, and GLP-1 medications are no exception. Research suggests that a meaningful portion of the weight lost on these drugs can come from lean mass, not just fat. This is a concern because muscle mass matters for metabolic health, bone density, and long-term function.

Resistance training and adequate protein intake (many clinicians recommend at least 1 gram per pound of ideal body weight per day) are important protective strategies. This is something to build into your plan from day one, not as an afterthought.

Pancreatitis

Acute pancreatitis, inflammation of the pancreas, is a rare but serious risk associated with GLP-1 medications. The absolute risk is low, but symptoms including severe abdominal pain radiating to the back warrant immediate medical attention. People with a personal or family history of pancreatitis should discuss this risk specifically with their doctor.

Thyroid Tumors

In rodent studies, GLP-1 receptor agonists were associated with thyroid C-cell tumors. This finding has not been replicated in human studies, but as a precaution, these medications carry a boxed warning (the FDA's most serious warning label) for a risk of medullary thyroid carcinoma. They are contraindicated in people with a personal or family history of medullary thyroid cancer or a condition called MEN2 syndrome.

Gastroparesis and Delayed Gastric Emptying

GLP-1 drugs slow down how quickly your stomach empties. For most people, this is part of why they work. But in some patients it can lead to a condition called gastroparesis, where the stomach empties too slowly. Symptoms include bloating, nausea, and a feeling of fullness that persists long after eating. There have also been reports of complications when patients undergoing surgery had undigested stomach contents despite fasting, so you should always tell your surgical team if you are on a GLP-1 medication.

Comparing the Key Medications

Understanding the differences between major GLP-1 and GIP/GLP-1 drugs can help you ask more targeted questions.

What This Means for Your Eligibility and Coverage

The expanding list of indications for GLP-1 medications is good news for patients who previously struggled to qualify for insurance coverage. A patient who has obesity and cardiovascular disease may now have a stronger case for insurance coverage of Wegovy than they did two years ago, because there is now an FDA-approved cardiovascular indication supporting the prescription.

Similarly, a patient with obesity and obstructive sleep apnea may qualify for Zepbound on that basis. These distinctions matter because insurers often follow FDA labeling closely when determining coverage.

If cost is a barrier, there are ways to reduce what you pay out of pocket. Manufacturer savings programs, telehealth providers with competitive pricing, and compounded versions (where available) all represent potential savings paths. You can explore current options through our GLP-1 Coupons page to see what is currently available.

Questions to Ask Your Doctor Before Starting

Going into a prescription appointment prepared will help you get more useful answers. Here are some questions worth raising:

• Do I have any conditions, such as pancreatitis, thyroid tumors, or a history of eating disorders, that make GLP-1 medications higher risk for me?
• Which specific medication and dose makes the most sense given my health history?
• What cardiovascular or metabolic conditions do I have that might actually benefit from a GLP-1 drug beyond weight loss?
• How should I adjust my protein intake and exercise routine to protect muscle mass?
• What early warning signs of serious side effects should prompt me to call you or seek emergency care?
• Are there other medications I take that could interact with a GLP-1 drug, particularly drugs for diabetes or blood pressure?

Having these conversations upfront, rather than after you have already started a prescription, will put you in a much stronger position.